BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Leveraging Vertical Integration to Target Precision Medicine Market

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to build vertical integration across telemedicine, pharmaceuticals, and clinical services. “At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific patient needs. This segment aims to tackle the growing gap in traditional pharmaceutical manufacturing… Through operating licensed compounding facilities, the company is strategically positioned to serve a niche but quickly evolving market driven by demand for precision treatment and specialized formulations,” reads the publication.

“In addition to this, the company’s telemedicine infrastructure operates as a front-end patient acquisition and engagement platform… ETST also strengthens its platform by using clinical service operations that support patient coordination and care continuity. Together, these segments help create a connected ecosystem that enables the company to engage across different points of the healthcare value chain, which is an increasingly important advantage in a space fast-moving toward integrated care models.”

To view the full article, visit https://ibn.fm/gHDgZ

About Earth Science Tech Inc.
Earth Science Tech operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The company’s current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC (“Mister Meds”), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN